PetMedix

PetMedix is a biomedical company specializing in the development of species-specific, therapeutic antibodies for pets. The company's focus lies in leveraging its skilled scientific team and harnessing decades of human clinical research to create a new generation of monoclonal antibody technology. This transformative technology offering aims to drastically enhance the range of therapeutic options available for pets. PetMedix was established in 2018 and has since cemented its place on the frontier of pet care solutions, delivering unprecedented quality of life improvements for companion animals.

Founded by Prof Allan Bradley FRS and Dr Jolyon Martin, PetMedix has demonstrated significant growth since its inception. With numerous milestones marking its journey, the company has constantly elevated the standards in pet care research and innovation. For instance, in 2017, Martin published the first comprehensive annotation of canine immunoglobulin loci in Immunogenetics. Throughout its development, PetMedix has secured critical funding, expanded its board of directors, and experienced robust company size growth. As of September 2021, the company raised $37M through its Series B round. In addition to these milestones, several partnerships and collaborations have been established to advance research and deliver promising therapeutic solutions, including a partnership with Boehringer Ingelheim in January 2021, an antibody discovery collaboration with Zoetis in January 2022, and the company's acquisition by Zoetis in August 2023.

PetMedix's compelling progress and dedication to revolutionizing pet care impart several reasons to pay keen attention to this company. From its groundbreaking research findings to its partnerships and awards, the company has consistently made strides towards improving pet health, testing boundaries in the realm of pet care solutions, and trailblazing antibody therapeutics. With a prestigious lineage that includes being a part of Zoetis, the world's biggest animal health pharma company, PetMedix ensures its contribution to pet care reaches and benefits a broad spectrum of pet-loving communities globally. The work from PetMedix's research hub lends value not only to the pet care industry but also to scientific understanding and progress. Therefore, PetMedix is truly an embodiment of innovation, pioneering, and commitment to the welfare of pets, making it a company to follow earnestly.

Connect